Alzheimer's drug embrace slows down as US doctors' reluctance grows
Fox News
The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy.
And those issues have played a role in slow adoption since the drug was approved by the U.S. Food and Drug Administration, according to interviews with 20 neurologists and geriatricians from rural, urban, academic and community practices in 19 states.
In interviews with Reuters, seven doctors treating patients for Alzheimer's attributed their own reluctance to prescribe Leqembi to concerns about the drug's efficacy, cost and risks.
More Related News